-- Mr. Amoroso Brings Significant Expertise in Oncology to New
Role --
SANTA MONICA, Calif.--(BUSINESS WIRE)--Jul. 9, 2018--
Kite, a Gilead Company (NASDAQ: GILD), announced today that Michael
Amoroso will join the company as Senior Vice President and Head of
Worldwide Commercial, Cell Therapy. In this position, Mr. Amoroso will
have responsibility for Kite’s commercial organization including sales,
marketing, market access, and healthcare provider and patient services.
Mr. Amoroso will begin his new role in August, reporting to John F.
Milligan, PhD, President and Chief Executive Officer of Gilead, and will
become a member of the Kite Cell Therapy Leadership Team.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180709005263/en/
Mr. Amoroso joins Kite from Eisai Inc., the U.S. pharmaceutical
subsidiary of Tokyo-based Eisai Co., Ltd., where he was Senior Vice
President, Americas Commercial for the company’s Oncology Business
Group. At Eisai, he was responsible for creating and driving commercial
strategies for the company’s approved products, pipeline assets and
late-stage compounds approaching commercialization. Prior to that, Mr.
Amoroso worked at Celgene Corp. for six years in a number of oncology
roles, before serving as Commercial Lead, Global Marketing for the
company’s CAR T programs. In this capacity, he helped Celgene develop an
organizational model to commercialize cell therapies involving
specialized manufacturing and customer services for patients with
lymphoma and myeloma. Before joining Celgene, Mr. Amoroso held marketing
and sales leadership positions at Sanofi SA, where he worked in oncology
and other therapeutic areas.
“Michael brings to the Kite organization significant expertise in the
area of oncology and in the commercialization of cancer products,”
commented Dr. Milligan. “This experience will help us as we seek to
build on our existing portfolio, expand our commercial presence in cell
therapy in the United States and around the world, and advance new
products to market. We are thrilled to welcome Michael to the
organization. We believe his leadership and proven track record will
help us accelerate our work to bring lifesaving therapies to people with
cancer.”
About Kite
Kite, a Gilead Company, is a biopharmaceutical company based in Santa
Monica, California. Kite is engaged in the development of innovative
cancer immunotherapies. The company is focused on chimeric antigen
receptor and T cell receptor engineered cell therapies.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that
discovers, develops and commercializes innovative medicines in areas of
unmet medical need. The company strives to transform and simplify care
for people with life-threatening illnesses around the world. Gilead has
operations in more than 35 countries worldwide, with headquarters
in Foster City, California.
Forward-Looking Statement
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors. These risks,
uncertainties and other factors could cause actual results to differ
materially from those referred to in the forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements.
These and other risks are described in detail in Gilead’s Quarterly
Report on Form 10-Q for the quarter ended March 31, 2018, as filed with
the U.S. Securities and Exchange Commission. All forward-looking
statements are based on information currently available to Gilead and
Kite, and Gilead and Kite assume no obligation to update any such
forward-looking statements.
For more information on Kite, please visit the company’s website at www.kitepharma.com.
Learn more about Gilead at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180709005263/en/
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.InvestorsSung Lee, 650-524-7792orMediaAmy
Flood, 650-522-5643
